Skip to main content

Table 1 General features of 17 refractory idiopathic systemic autoimmune myopathies

From: Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series

No Disease Disease
(years)
Treatment Activity CPK (U/L) Prednisone (mg/day)*
Previous Immediately Before MMF Current Initial 6 months after MMF treatment Initial 6 months after MMF treatment Inicial 6 months after MMF treatment
1 PM 2 MP,Pred,Aza,CYC CP CP, MMF P P 95 130 5.0 20.0
2 DM 2 Pred,Aza,MTX,CYC AZA MMF P Remission 48 66 15.0 5.0
3 ASS 1 MP,Pred,IVIg,Aza,MTX,CYC CYC MMF Mu,C,P Mu 242 139 20.0 10.0
4 ASS 2 Pred,Aza,MTX,CYC MTX MTX, MMF Mu,C Remission 167 200 10.0 5.0
5 DM 8 Pred,AM,Aza,CP,RTX,Tac AM,Tac AM, Tac, MMF Mu,C C 141 53 15.0 20.0
6 DM 3 Pred,Aza,MTX AZA AZA, MMF Mu,C Mu 268 148 15.0 7.5
7 DM 2 MP,Pred,Aza,MTX MTX MMF Mu Mu 40 20 50.0 30.0
8 DM 6 MP,Pred,Aza,MTX,CP MTX,CP CP, MMF Mu Mu 249 2120 10.0 15.0
9 PM 6 MP,Pred,Aza,MTX AZA AZA, MMF Mu Mu 1534 3517 5.0 0
10 DM 1 MP,Pred,Aza,CYC,RTX RTX RTX, MMF Mu Mu 215 255 15.0 2.5
11 PM 1 Pred,Aza,MTX - MMF Mu Mu 118 205 60.0 5.0
12 DM 1 MP,AM,AZA,MTX AZA MMF Mu Mu 35 30 40.0 5.0
13 DM 1 MP,Pred,AZA,MTX MTX MTX, MMF Mu Remission 245 257 10.0 0
14 DM 5 MP,AM,AZA,MTX,CP AZA,CP AZA, MMF Mu Mu 858 268 10.0 0
15 DM 1 Pred,AZA,CYC - MMF C,P C 114 138 15.0 5.0
16 DM 1 MP,Pred,MTX MTX MTX, MMF C Remission 100 80 12.5 5.0
17 CADM 3 Pred,AZA,MTX,LFN,CYC AZA,LFN AZA, MMF C C 79 95 60.0 2.5
  2.0
(1.0-4.0)
        15.0
(10.0-30.0)
5.0
(2.5-12.5)
  1. AM antimalarials, ASS anti-synthetase syndrome, AZA azathioprine, CPK creatine phosphokinase, CP cyclosporine, C cutaneous, CADM clinically amyopathic dermatomyositis, CYC cyclophosphamide, DM dermatomyositis, F female, IVIg intravenous human immunoglobulin, LFN leflunomide, M male, MP methylprednisolone pulse therapy, MTX methotrexate, Mu muscular, PM polymyositis, P pulmonary, Pred prednisone, RTX rituximab, Tac tacrolymus
  2. *Pred: current vs. 6 months: P = 0.005